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The treatment of melanoma has remained a difficult challenge. Targeting the tumor
stroma has recently attracted attention for developing novel strategies for melanoma
therapy. Activating transcription factor 3 (ATF3) plays a crucial role in regulating
tumorigenesis and development, but whether the expression of ATF3 in human dermal
fibroblasts (HDFs) can affect melanoma development hasn’t been studied. Our results
show that ATF3 expression is downregulated in stromal cells of human melanoma.
HDFs expressing high levels of ATF3 suppressed the growth and migration of melanoma
cells in association with downregulation of different cytokines including IL-6 in vitro. In
vivo, HDFs with high ATF3 expression reduced tumor formation. Adding recombinant
IL-6 to melanoma cells reversed those in vitro and in vivo effects, suggesting that
ATF3 expression by HDFs regulates melanoma progression through the IL-6/STAT3
pathway. More importantly, HDFs pretreated with cyclosporine A or phenformin to induce
ATF3 expression inhibited melanoma cell growth in vitro and in vivo. In summary, our
study reveals that ATF3 suppresses human melanoma growth and that inducing the
expression of ATF3 in HDFs can inhibit melanoma growth, a new potential melanoma
therapeutic approach.
Keywords: melanoma, fibroblasts, stromal cells, activating transcription factor 3, interleukin 6
INTRODUCTION
Human cutaneous melanoma originates from dysregulated proliferation of melanocytes and is
one of the most aggressive and deadly forms of skin cancer, accounting for more than 80% of
skin cancer-related deaths (1). Despite recent advances in melanoma therapy including the use
of immune checkpoint inhibitors (2, 3), treatment options for metastasized melanoma are still
very insufficient (4). The activating BRAF mutation has been considered to be a main factor
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driving the initiation of melanoma (5). However, ∼80% of
benign melanocytic nevi contain BRAF-activating mutation,
although only a small percentage of them will develop into
malignant melanoma (6). The mechanism underlying malignant
transformation from nevus tomelanoma is therefore still unclear.
Recent research studies have shown the changes of stroma
cells play essential roles in tumor initiation (7, 8). The main
component of the tumor microenvironment is the activated
fibroblasts in cancers, which called cancer-associated fibroblasts
(CAFs) (9). A large number of studies demonstrated that CAFs
secrete numerous cytokines and growth factors which promote
tumor growth and metastasis (10–13). Kim’s (14) research
showed that senescent CAFs can promote melanoma initiation
and development, suggesting that tumor microenvironment
changes may play important roles in melanoma initiation and
development. Therefore, targeting CAF may provide a potential
new therapeutic approach for treatment of melanoma in the
clinic (3, 15).
Activating transcription factor 3 (ATF3) is a key transcription
factor in cellular stress responses, with different expression levels
and functions in different tissues (16). It has been shown that
ATF3 can be either an oncogene or a tumor suppressor gene
depending on the type of tumor (17–21). For instance, ATF3
was found to be down-regulated in esophageal squamous cell
carcinoma (ESCC) lesions, and forced expression of ATF3 led to
decreased growth and invasive properties of ESCC cells in vitro
and in vivo through regulation of MDM2 expression (22). On
the other hand, we described earlier that upregulation of ATF3 in
human skin epidermal cells blocks p53-dependent senescence to
promote tumorigenesis in the skin (23). ATF3 is also expressed in
human dermis, but hardly anything is known about its function
in human dermal fibroblasts (HDFs) or melanoma-associated
fibroblasts. Therefore, the present study aims to investigate
whether the expression level of ATF3 in dermal fibroblasts can
affect melanoma cell growth and migration.
MATERIALS AND METHODS
In vitro Cell Culture
Primary HDFs were isolated from foreskin tissues following
a protocol described previously (24, 25). The HDFs and
human melanoma cell lines Mel-JuSo and UACC62 were
cultured in Dulbecco’s Modified Eagle’s medium (DMEM,
Gibco, USA) supplemented with 10% FBS (Biological Industries,
Israel), penicillin (100 units/ml) and streptomycin (100µg/ml)
(ThermoFisher, USA) (complete medium) at 37◦C in a
humidified 5% CO2 atmosphere.
RNA Extraction and Real-Time Quantitative
Reverse Transcription PCR (qRT-PCR)
Total RNA was extracted from HDFs and melanoma cells using a
Takara MiniBEST Universal RNA Extraction Kit (Takara, Japan),
and 1 µg of total RNA was reverse transcribed into cDNA
using a Primer Script RT Reagent Kit (Takara, Japan). All qRT-
PCR amplification cycles were performed using SYBR Premix
Ex Taq (Tli RNaseH Plus) (Takara, Japan) with a Light Cycler
480 II (Roche Diagnostics, Mannheim, Germany) according to
the manufacturer’s protocol. Amplification conditions were set
to an initial step of 95◦C for 30 s followed by 45 cycles of 95◦C
for 5 s, 60◦C for 35 s, 72◦C for 60 s, and then a final step of 40◦C
for 30 s. All RNA samples were analyzed in triplicate with gene-
specific primers along with primers for human ribosomal protein
mRNA RPLP0 (H36B4), which was used as a housekeeping gene
for normalization. The list of gene-specific primers is provided in
Supplementary Table 1.
Western-Blot Analysis
Cells were harvested at the indicated time points and rinsed
with ice-cold PBS. Cells were lysed in radioimmunoprecipitation
assay buffer (RIPA buffer, Beyotime Institute of Biotechnology,
Shanghai, China) containing 1% phenylmethylsulfonyl fluoride
(PMSF, Beyotime Institute of Biotechnology, Shanghai, China)
for 30min on ice and then centrifuged at 12,000 rpm for
15min at 4◦C. The protein concentration of each sample was
measured using a bicinchoninic acid assay kit (BCA Protein
Assay Kit, Beijing Solarbio Science & Technology). Equal
amounts (30 µg) of protein samples were electrophoresed
in 10 or 12% sodium dodecyl sulfate-polyacrylamide gels
(Beyotime Institute of Biotechnology) and electrically transferred
to 0.45µm polyvinylidene fluoride (PVDF) membranes (Merck
Millipore, USA). The membranes were blocked with 5% non-
fat milk at room temperature for 1 h and then incubated with
primary antibodies at 4◦C overnight. GAPDH was used as
loading control. The next day, the membranes were washed
with Tris-based saline-Tween-20 (TBS-T, 20 mmol/ml Tris-
HCl, 150 mmol/ml NaCl and 0.05% Tween 20) three times
for 10min each, and then the membranes were incubated with
secondary antibodies for 1 h at room temperature. The protein
bands were visualized using a Chemiluminescent HRP Substrate
Kit (Millipore, Billerica, MA, USA) and MiniChem 610 Image
system (Sagecreation, Beijing). The levels of protein expression
were normalized to the corresponding GAPDH bands using
ImageJ software. The list of primary and secondary antibodies is
provided in Supplementary Table 2.
Generation of Conditioned Media
To prepare conditioned media (CM), HDFs with or without
ATF3 overexpression were cultured to reach 80% confluence
in 10 cm dishes, then the medium was replaced with fresh
complete medium. Alternatively, either phenformin (1.5mM)
or cyclosporine A (10µM) was added to an HDF culture
for 24 h before replacing the medium with fresh drug-free
medium. Forty-eight hours later, the media were collected and
filtered through 0.22µm PES filter (Merck Millipore Ltd. USA)
to remove cells and cellular debris. The media were used
immediately or aliquoted and kept at −80◦C for later use for
culture of melanoma cells.
ELISA
ELISA assays were carried out using R&D Systems kits
according to the manufacturer’s protocols. Briefly, total protein
concentrations in CMwere measured using a BCA Protein Assay
Kit (Solarbio Science & Technology, Beijing), then CM were
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diluted to suitable concentrations for measurements of IL-6, IL-
8, and TNFα using the following ELISA kits: Human IL-6 ELISA
Kit (Cat. No. VAL102, R&D Systems, USA), human IL-8 ELISA
Kit (Cat. No. VAL103, R&D Systems, USA) and human TNFα
ELISA Kit (Cat. No. VAL105, R&D Systems, USA). Absorbance
at 450 nm was measured using a plate reader (Spectrostar Nano,
BMG Labtech) and the concentrations of IL-6, IL-8, and TNFα in
CM were calculated from the respective standard curves.
Immunofluorescence and
Immunohistochemical Staining
Immunofluorescence (IF) and immunohistochemical (IHC)
staining were performed followed standard protocols. Five
micrometer thick sections were cut from formalin-fixed paraffin-
embedded clinical tissue blocks and the sections on slides were
deparaffinized, rehydrated, immersed in 0.3% hydrogen peroxide
to block endogenous peroxidase, and then submerged in EDTA
antigen retrieval solution (ZSGB-BIO, Beijing) for heat-induced
antigen retrieval according to the manufacturer’s protocol. After
blocking with 10% goat serum, the slides were incubated with
primary antibodies at 4◦C overnight. On the second day, the
slides were washed with PBS (3 × 10min). For IF staining,
the slides were incubated for 1 h with DyLight488 goat anti-
mouse IgG(H+L) (Multi Science, Hangzhou) and DyLight594
goat anti-rabbit IgG(H+L) (Multi Science, Hangzhou) at room
temperature in the dark. Sections were then incubated with
4’, 6-diamidino-2-phenylindole (DAPI, Abcam, USA) to stain
nuclei. For IHC staining, the slides were incubated for 1 h
with rabbit biotin-streptavidin HRP secondary antibody (ZSGB-
BIO, Beijing). After washing 3 times with PBS, the sections
were incubated with DAB staining solution (ZSGB-BIO, Beijing)
for 5min, counterstained with hematoxylin, dehydrated and
mounted. An immunofluorescence microscope (Olympus BX53-
DP80, Tokyo, Japan) was used for analysis of staining.
For quantification of ATF3 nuclear staining, has been linked
to its activation (26–28), all staining of clinical tumor tissues
was performed twice and was evaluated by two independent
investigators. Evaluations were based on arbitrary units as
follows: 0: no staining; 1: intermediate (weak and incomplete)
nuclear staining; 2: strong, complete nuclear staining. For the
relative quantification of ATF3 expression, the mean value of the
independent measurements was taken as the final score.
RNAscope in situ Hybridization Analysis
In situ hybridization with ATF3-specific RNAscope Probe-Hs-
ATF3 (Cat. No.470861, Advanced Cell Diagnostics, Inc. USA)
was performed according to the RNAscope 2.5 RED Assay
Protocol (#322452 and #322360). Briefly, paraffinized tissue slides
were baked at 60◦C for 1 h and then deparaffinized. Sections
were immersed in RNAscope Hydrogen Peroxide for 10min
and then submerged in RNAscope Target Retrieval Reagent
at 100◦C for 15min for target retrieval. Sections were then
incubated in RNAscope Protease Plus reagent in a HybEZ II
hybridization oven at 40◦C for 30min. Tissue slides were then
incubated with RNAscope Probe-Hs-ATF3, or with RNAscope
Negative Control Probe dapB (Cat. No. 310043) as negative
control or RNAscope Probe Hs-PPIB (Human-Peptidylprolyl
Isomerase B) (Cat. No. 313902) as positive control (as shown in
Supplementary Figure 1), in the hybridization oven at 40◦C for
2 h, followed by successive incubations with Hybridize Amp 1–6
reagents. Then the signals were detected with RNAscope 2.5 Red
signal detecting reagent and the tissues were counterstained with
hematoxylin solution and mounted. Tissues exhibiting red-dyed
points were considered positive.
Cell Proliferation Assay
Melanoma cells were seeded in 96-well plates at a density of
2,000 cells/well in triplicate and grown overnight in complete
medium. Then the medium in all wells was replaced with CM
every 48 h. At every assay time point, 10 µl of Cell Counting Kit-
8 (CCK-8) (Dojindo, Japan) working solution was added to each
well and cultured for 1.5 h at 37◦C. Absorbance at 450 nm was
measured using a plate reader (Spectrostar Nano, BMG Labtech).
The experiments were repeated at least three times.
Colony Formation Assay
Melanoma cells were plated in 6-well plates at 1,500 cells/well
and grown overnight. The cell culture medium was replaced with
CM every 2 days for 14 days. At the end of the cell culture,
cells were washed with PBS, fixed with 4% paraformaldehyde
solution (Sigma-Aldrich, USA) and stained with 0.1% crystal
violet (Solarbio Science & Technology, Beijing). Cell colonies
with more than 50 cells were counted under an inverted
microscope (Olympus CKX41, Tokyo, Japan). The experiments
were performed in triplicate and repeated at least three times.
Co-culture Assay
The co-culture assay was performed using cell culture inserts
with 3µm pore diameter membranes (Millipore, Cat. No.
MCSP12H48, USA) in 12-well tissue culture plates. AT3-
overexpressing or control HDFs (100,000 cells in 1ml DMEM
medium containing 3% FBS) were seeded on the bottom wells of
the plate and 20,000 melanoma cells in 300 µl DMEM medium
containing 0.5% FBS were seeded in the cell culture inserts in
the wells. At every assay time point, melanoma cells on insert
membranes were collected by trypsin digestion and counted with
both a Countstar IC 1000 automated cell counter (ALIT Life
Science Co. Limited) and a hemocytometer. The experiments
were performed in triplicate and repeated at least three times.
Cell Migration Assay
The cell migration assay was performed using cell culture inserts
with 8µm pore diameter membranes (Falcon, USA) in 24-well
plates. 60,000 ATF3-overexpressing or control HDFs in 500 µl
of complete medium were seeded per well and cultured for 48 h,
or 500 µl per well of conditioned medium was added to empty
wells just before adding melanoma cells to the cell culture inserts.
40,000 melanoma cells in 200 µl DMEM medium containing
0.5% FBS were seeded in the inserts placed in the wells of the
24-well plates. The plates were incubated at 37◦C for 24 h. Cells
that migrated through the insert membrane were fixed with 4%
paraformaldehyde solution (Sigma-Aldrich, USA) and stained
with 0.1% crystal violet (Solarbio Science & Technology, Beijing).
Images of five randomly selected fields of the fixed cells were
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captured and the cells were counted. The experiments were
repeated at least three times.
Wound Healing Assay
Melanoma cells were incubated in complete medium in 6-well
plates. When the cells reached more than 90% confluency, the
cell monolayer was scratched with a sterile 10 µl pipette tip (time
0), washed with PBS to remove the cells within the linear scratch
and refreshed with CM. Pictures of 5 non-overlapping fields
were photographed at 0 h and 24 h using an inverted microscope
(Olympus CKX41, Tokyo, Japan). The percentage of wound
healing was reported as the healing area width divided by the
total wound area width. The experiments were repeated at least
three times.
Construction of ATF3-Targeting
CRISPR/Cas 9
The oligonucleotide sequences of two ATF3 small guide RNAs
(sgRNA1, sgRNA2) were designed and identified using the Broad
Institute CRISPR design tool (http://crispr.mit.edu/). All 20-bp
sequences preceding an NGG protospacer-adjacent motif were
analyzed for potential off-target sites in the human genome
using BLAST searches of whole genome DNA sequences. We
purchased the lentiviral vector pSpCas9(BB)-2A-Puro (PX459)
V2.0 (Plasmid #62988), which expresses SpCas9 under the
transcriptional control of a cytomegalovirus promoter, from
Addgene and sgRNA1 and sgRNA2 were cloned into the plasmid
according to the protocol published by Feng Zhang’s Lab (29).
The upstream and downstream oligonucleotides for each sgRNA
were phosphorylated, annealed, and then subcloned into the
pSpCas9 (BB)-2A-Puro (PX459) V2.0 vector. The ATF3 sgRNA1
and sgRNA2 sequences used in this study are provided in
Supplementary Table 1.
Virus Preparation and Infection
Retrovirus and lentivirus preparation and infection were
performed as described previously (23). HEK 293T cells were
transfected with viral expression vector together with packaging
vector using Lipofectamine 3000 Kit (Invitrogen, USA) following
the manufacturer’s protocol, and virus particles were collected at
24, 48, and 72 h after transfection. HDFs were seeded in 10 cm
dishes and incubated until the cell density reached 60–80%, and
then the cells were incubated with 6ml virus plus 5 µl polybrene
solution (10 mg/ml, Sigma-Aldrich, USA) for 6 h. The virus-
containing medium was then removed, the cells were washed
with PBS, and then the HDFs were incubated with normal
DMEM growth medium supplemented with 1µg/ml puromycin
(Sigma-Aldrich, USA) for 48 h to select for transduced cells.
The surviving fibroblasts were validated for ATF3 deletion by
Western blot.
In vivo Tumor Assay
Tumor xenografts were grown and measured as described
previously (23). To test the inhibitory effect of ATF3-
overexpressing HDFs plus/minus IL-6 treatment on melanoma
cell growth in vivo, 8 week-old female nude/nude mice (Charles
River Laboratory, Wilmington, MA, USA) were randomly
assigned to three groups: (1) the control NEO group (NEO)
with subcutaneous injection of UACC62 melanoma cells mixed
with NEO-expressing HDFs plus intraperitoneal injection of PBS
after grafting, (2) the AFT3 overexpression group (ATF3-OE)
with injection of UACC62 cells mixed with ATF3-overexpressing
HDFs plus intraperitoneal injection of PBS after grafting, and (3)
the rhIL-6 treatment group with injection of UACC62 cells mixed
with ATF3-overexpressing HDFs plus intraperitoneal injection
of recombinant human IL-6 (Cat. No. Z03034-10, GenScript,
Nanjing) at 100 ng/kg/day/mouse (3 mice per group). Each
injection contained 0.5 million UACC62 melanoma cells and
0.5 million HDFs, and each mouse received injections at 4
different sites. Three weeks after grafting, mice were euthanized
for measurements of tumor volumes and tumor weights.
To test whether HDFs pretreated with cyclosporine A (CsA)
affect melanoma cell growth, HDFs were treated with either
10µM CsA or DMSO (as control) for 24 h, then the cells were
collected and mixed with UACC62 melanoma cells at a 1:1 ratio.
The cell mixture was injected subcutaneously into the back skin
of 8-week-old female nude/nude mice at 4 different sites (total of
1 million cells per injection site). Four mice per group were used
and the mice were euthanized 3-weeks after grafting for analysis
of tumor volumes and tumor weights. The in vivo experiments
were performed 3 times.
Statistical Analysis
All quantification data are summarized as the mean ± standard
error of the mean (SEM) of at least three biological replicates
of each experiment in all cases. GraphPad Prism 6 (GraphPad
Software Inc., LaJolla, CA, USA) was used for statistical analysis.
Student’s t-test was used for comparison of 2 groups; one-
way or two-way ANOVA with correction for multiple pairwise
comparisons was used when comparing more than 2 groups with
one or two independent variables, respectively. The p-values from
the statistical analyses are indicated in the figures.
RESULTS
Clinical Melanoma Stromal Cells Express
Low Levels of ATF3
To investigate the expression level of ATF3 in human melanoma
stromal cells, clinical melanoma samples were analyzed by
immunohistochemistry staining with S100 (30–32) and ATF3
antibodies. Tumor cells identified by positive S100 staining
(black arrows, left panel, Figure 1A) expressed clearly detectable
amounts of ATF3 (black arrows, right panel, Figure 1A), while
melanoma stromal cells identified by their spindle shapes and
absence of S100 protein displayed extremely weak ATF3 staining
(red arrows, right panel, Figure 1A). Next, RNAscope technology
was performed to detect ATF3 mRNA within intact cells. We
found strong ATF3 signals in the tumor cells but not in
the stromal cells, as indicated in Figure 1B (right panel, red
arrows), and no positive staining with the negative control probe
(Figure 1B, left panel). Finally, double immunofluorescence
staining of vimentin and ATF3 was carried out in melanoma
tumor samples, melanocytic nevi and normal skin tissues. As
shown in Figure 1C, we observed in benign nevi and normal
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FIGURE 1 | Low expression of ATF3 in human melanoma stromal cells. (A) Immunohistochemistry staining for S100 and ATF3 in clinical melanoma tissues. Black
arrows indicate melanoma cells and red arrows indicate stromal cells. (B) RNAscope in situ hybridization staining for ATF3 and negative control (NC) in melanoma
samples. Red arrows indicate stromal cells. (C) Double immunofluorescence staining of ATF3 (red) and vimentin (green) in normal skin, melanocytic nevus and
melanoma tissues. White arrowheads indicate stromal cells with positive staining of both vimentin (green) and ATF3 (red); white arrows indicate stromal cells with
vimentin positive and ATF3 negative staining. (D) Relative scores of ATF3 protein expression levels in stromal cells, detected by vimentin staining as in (C) and
quantified nuclear staining of ATF3 from all staining of 15 normal human skin, 15 melanocytic nevus and 17 melanoma tissues. Data are presented as the mean ±
standard deviation, *p < 0.05. All scale bars represent 20µm.
skin tissues that vimentin-expressing stromal cells expressed
ATF3 (stained red, white arrow heads, Figure 1C), while the
majority of vimentin+ cells in malignant melanoma did not
express detectable ATF3 (white arrows, Figure 1C). Quantitative
analysis of ATF3 nuclear staining indicated with DAPI (blue)
in stroma cells, which recognized by vimentin positive staining
confirmed that the lowest ATF3 staining was in the stroma
cells of the malignant melanoma tumor tissues (Figure 1D).
These data suggest that the decreased expression of ATF3 in
the tumor stromal cells correlate with the development of
malignant melanoma.
HDFs Overexpressing ATF3 Inhibit
Melanoma Cell Growth and Migration in
Co-culture Assays
Next, we investigated the effects of ATF3 overexpression
in fibroblasts on melanoma function in vitro. ATF3 was
stably overexpressed (ATF3-OE) in three different primary
HDF cultures by retroviral transduction, resulting in 5–8-fold
increased expression of ATF3 in the three strains compared
with mock (NEO) transduced cells (Figures 2A,B). In order
to minimize artificial effects induced by overexpressed ATF3,
the HDF line with the lowest expression of ATF3 after virus
infection (strain 0808) was used for the following studies. A co-
culture assay shows that the numbers of Mel-JuSo and UACC62
melanoma cells co-cultured with ATF3-overexpressing HDFs
were significantly less than the numbers of melanoma cells co-
cultured with control HDFs (Figures 2C,D). Then, we tested
the effects of ATF3 overexpression in HDFs on melanoma cell
migration. As shown in Figure 2E, both Mel-JuSo and UACC62
melanoma cells migrated significantly less when co-cultured with
ATF3-overexpressing HDFs than when co-cultured with NEO-
expressing HDFs. These results suggest that increased expression
of ATF3 in HDFs can inhibit both growth and migration of
melanoma cells.
To test the effect of reducing ATF3 expression in HDFs, we
engineered deletion of the ATF3 gene by lentiviral-mediated
CRISPR/Cas9 genome editing. Efficient loss of ATF3 protein
was confirmed by Western blot (Supplementary Figure 2A).
Co-culture of ATF3-deleted HDFs with Mel-JuSo or UACC62
melanoma cells did not affect melanoma cell growth or migration
(Supplementary Figures 2B–D), suggesting that endogenous
ATF3 levels in in vitro cultured HDFs are insufficient to affect
melanoma growth or migration significantly. This result agrees
with a recent in vivo study by Avraham et al. showing that the
growth of Lewis Lung Carcinoma cells was not affected when
transplanted onto ATF3 knockout mice, but was promoted when
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FIGURE 2 | ATF3-overexpressing human dermal fibroblasts (HDFs) inhibited melanoma cell proliferation and migration in co-culture assays. (A) qRT-PCR analysis of
ATF3 mRNA levels and (B) Western blot analysis of ATF3 protein with GAPDH as loading control, in three HDF strains infected with ATF3-expressing (ATF3-OE) or
control neomycin (NEO)-expressing retrovirus. (C,D) The numbers of Mel-JuSo (C) and UACC62 (D) melanoma cells after co-culture for the indicated number of days
with the 3 HDF strains overexpressing ATF3 (ATF3-OE) or expressing NEO. (E) Images (left panels) and quantification (graphs) of Mel-JuSo and UACC62 cells that had
migrated after co-culture for 24 h with ATF3-OE or control NEO HDFs. Bars represent 100µm. Data are presented as the mean ± standard deviation, *p < 0.05, **p
< 0.01, ***p<0.001.
transplanted onto ATF3 and JDP2 (c-Jun dimerization protein 2)
double knockout mice (17).
ATF3-Overexpressing HDFs Inhibit
Melanoma Cell Growth and Migration
Through a Paracrine Signaling Pathway
The above co-culture assay results suggested that the ATF3-
overexpressing HDFs inhibited melanoma cell growth and
migration through a paracrine signaling pathway. To further
support this hypothesis, we grew melanoma cells in conditioned
medium (CM) collected from cultures of ATF3-overexpressing
HDFs. We found that CM from ATF3-overexpressing HDFs
significantly decreased the growth of Mel-JuSo and UACC62
cells compared with CM from NEO-expressing control HDFs
(Figures 3A,B). In addition, a cell colony assay showed that
CM derived from ATF3-overexpressing HDFs inhibited colonic
growth of melanoma cells significantly (Figure 3C). Next, we
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FIGURE 3 | Conditioned medium (CM) derived from ATF3-overexpressing HDFs inhibited melanoma cell growth and migration. CM derived from either ATF3-OE or
control NEO HDFs were used for all conditions. (A,B) The proliferation of melanoma cells was analyzed at the indicated times. (C) Colony formation assay was
performed; the lower panel graphs show the average number of colonies formed in each group. (D) Melanoma cells that had migrated after 24 h of culture; the
average numbers of migrated cells are shown in the lower panel graphs. (E,F) Wound healing assay, images of the cells right after scratching (0H) and 24 h after
scratching (24H) are shown in the left panel and percentages of wound closure at 24 h are shown in the right panel graphs. Data are presented as the mean ±
standard deviation, *p < 0.05, **p < 0.01. The scale bars represent 5mm (C) and 100µm (D,E).
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tested whether CM affects melanoma cell migration. Indeed,
CM from ATF3-overexpressing HDFs inhibited migration of
both Mel-JuSo and UACC62 melanoma cells compared with
CM fromNEO-expressing HDFs (Figure 3D), which was further
confirmed by a scratch migration assay (Figures 3E,F). Taken
together, these data suggest that overexpression of ATF3 in HDFs
decreases the secretion of soluble factors that play crucial roles in
melanoma cell growth and migration.
Overexpression of ATF3 Significantly
Decreased the Expression of IL-6, IL-8, and
Other Cytokines in HDFs
ATF3 has previously been shown to downregulate expression
of many cytokines including IL-6 and IL-8 (33). Therefore,
we examined the effects of ATF3 levels on the expression of
potentially relevant cytokines and growth factors in HDFs.
First, qRT-PCR analysis showed that the expression levels
of interleukin genes such as IL-1β, IL-6 and IL-8, as well
as cyclooxygenase genes COX1 and COX2, are significantly
lower in ATF3-overexpressing HDFs compared with control
HDFs (Figure 4A). To test whether depletion of ATF3
could affect the expression of these genes in HDFs, we
performed qRT-PCR analysis of the genes in ATF3-KO HDFs.
Interestingly, we found that only IL-6 and IL-8 expression
increased significantly after ATF3 deletion (Figure 4B),
which could also explain why the ATF3 knockout HDFs did
not have a significant effect on melanoma cell growth and
migration (Supplementary Figure 2). Secondly, enzyme-linked
immunosorbent assays (ELISA) were performed to measure
cytokine protein levels in CM from HDF cultures. ATF3
overexpression resulted in significantly reduced levels of IL-6
and IL-8, but did not affect TNFα levels in CM, consistent
with the qRT-PCR results for those cytokines (Figure 4C).
The inhibition of IL-6 levels by ATF3 overexpression was
especially notable (3-fold decreased, Figure 4C, left graph).
Again, the protein levels of IL-6, IL-8, and TNFα in CM were
not affected by ATF3 deletion in HDFs (Figure 4D), differing
somewhat from the small but significant increases in IL-6 and
IL-8 mRNAs after ATF3 deletion. Taken together, the data
above suggest that ATF3 overexpression in HDFs markedly
inhibits the expression and secretion of cytokines including
IL-6 and IL-8.
Suppression of IL-6 Expression Is Crucial
to the Inhibitory Effects of
ATF3-Overexpressing HDFs on Melanoma
Cell Growth and Migration
Cytokines produced in the tumor microenvironment have been
shown to play important roles in different stages of cancer
development (3, 34). Thus, it is likely that the decreased
production of cytokines in HDFs overexpressing ATF3 may be
critical for the inhibition of melanoma cell growth andmigration.
IL-6, a pro-inflammatory cytokine, has been well-documented
to play important roles in development and progression of
melanoma (35), and its expression was markedly reduced
in ATF3-overexpressing HDFs. Therefore, we tested whether
replenishment of IL-6 could counteract the effects of ATF3-
overexpressing HDFs on melanoma cell growth and migration.
We added recombinant human IL-6 protein (rhIL-6) to CM
derived fromHDFs overexpressing ATF3 and performed growth,
colony formation and migration assays. We found that addition
of rhIL-6 to CM from ATF3-overexpressing HDFs reversed the
inhibitory effect of the CM on proliferation of melanoma cells
(Figures 5A,B) and restored the colony growth of both UACC62
(Figure 5C) and Mel-JuSo (Supplementary Figure 3A) cells to
control levels. Finally, both cell migration and wound healing
assays showed that addition of rhIL-6 blocked the inhibitory
effects of CM from ATF3-overexpressing HDFs on melanoma
cell migration (Figures 5D,E, Supplementary Figures 3B,C).
Taken together, these data suggest that suppression of IL-
6 expression plays a crucial role in the inhibitory effect of
ATF3-overexpressing HDFs on melanoma cell proliferation
and migration.
It is well-known that IL-6 drives many “hallmarks” of cancer
through downstream activation of the Janus kinase/signal
transducer and activator of transcription 3 (JAK/STAT3)
signaling pathway (36, 37). In agreement with the previous
studies, we found that phosphorylation of STAT3 in both
Mel-JuSo and UACC62 melanoma cells decreased dramatically
after culture with CM derived from ATF3-overexpressing
HDFs. Interestingly, other signaling pathways including
the NF-κB, PI3K/AKT, and MAPK pathways, were not
altered in the melanoma cells cultured with CM from
ATF3-overexpressing HDFs (Figure 5F). Taken together,
these data suggest that decreased production of IL-6 in
ATF3-overexpressing HDFs contributes to inhibition of
melanoma cell proliferation and migration by blocking the
STAT3 pathway.
HDFs With High Expression of ATF3
Repress Melanoma Cell Tumor Formation
and Growth in vivo
To illustrate the in vivo biological function of HDFs with high
level expression of ATF3, UACC62 melanoma cells mixed with
ATF3-overexpressing HDFs or NEO-expressing control HDFs
were subcutaneously injected into the back skin of nude/nude
mice. The mice injected with ATF3-overexpressing HDFs were
then divided into two groups with or without intraperitoneal
injection of rhIL-6 (Figure 6A). At 3-weeks after injection,
the tumors were collected and weighted. The average size of
tumors grown with ATF3-overexpressing HDFs (without rhIL-
6) was smaller than the average sizes of tumors grown with
NEO-expressing control HDFs or with ATF3-overexpressing
HDFs plus intraperitoneal injection of rhIL-6 (Figure 6A). The
number and average weight of tumors that formed in the mice
that received ATF3-overexpressing HDFs without rhIL-6 were
significantly lower than in the other two groups (Figures 6B,C).
These in vivo experiments validated our in vitro findings by
showing that HDFs with high expression of ATF3 can repress
melanoma cell tumor formation and growth, probably through
negative regulation of IL-6 production.
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FIGURE 4 | ATF3 overexpression suppressed expression of pro-inflammatory cytokines IL-6 and IL-8 in HDFs. (A) The mRNA levels of cytokine, growth factor and
CAF-related genes were measured by qRT-PCR in ATF3-OE HDFs and control NEO HDFs. (B) The mRNA levels of the same genes as in (A) were measured by
qRT-PCR in two HDF pools with CRISPR/Cas9-mediated ATF3 deletion by independent small guide RNAs (ATF3-SG1 or ATF3-SG2) and compared with the mRNA
levels in control HDFs transduced with empty vector (CON-V). (C,D) Protein concentrations of IL-6, IL-8 and TNFα measured by ELISA in CM derived from ATF3-OE
or control NEO HDFs (C) and in CM from HDFs with CRISPR/Cas9-mediated deletion of ATF3 (ATF3-SG1 or ATF3-SG2) or control vector (CON-V) (D). Data are
presented as the mean ± standard deviation, *p < 0.05, **p < 0.01.
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FIGURE 5 | ATF3-overexpressing HDFs inhibit melanoma cell proliferation and migration through regulation of the IL-6/STAT3 pathway. (A–F) CM derived from either
ATF3-OE or control NEO HDFs, or from ATF3-OE HDFs incubated with 10 ng/ml recombinant human IL-6 (ATF3-OE + rhIL-6) were used to culture melanoma cell
lines Mel-JuSo and UACC62 for analysis of growth (A,B), colony formation (C), transwell-migration (D), wound healing (E), and phosphorylated (active) states of the
indicated signaling proteins (F). Quantification results for C-F assays are shown in the graphs at right. The relative levels of phosphorylated STAT3 in F were
normalized to the respective total STAT3 bands. The scale bars in the images represent 5mm (C) and 100µm (D,E). Data are presented as the mean ± standard
deviation, *p < 0.05, **p < 0.01.
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FIGURE 6 | ATF3-overexpressing HDFs inhibit melanoma formation and growth in vivo. (A) Mice and tumors collected at 3 weeks after grafting with the indicated
conditions. rhIL-6 (100 ng/mouse/day) was administrated by intraperitoneal injection. (B) The percentage of tumor formation. (C) The average weight of tumors. (D,E)
HDFs pretreated with 1.5mM phenformin (Phen.), 10µM CsA, or DMSO vehicle (CON) for 24 h were collected at the indicated times for analysis of ATF3, IL-6, and
IL-8. (F,G) CM derived from pretreated HDFs was analyzed for IL-6 and IL-8 levels. (H,I) CCK-8 assay after culturing melanoma cells with CM from pretreated HDFs at
the indicated time points. (J,K) Mice and tumors collected 3 weeks after grafting as indicated conditions. The percentage of tumor formation and the average tumor
weight are shown in (K). The scale bars: 5mm. Data are presented as the mean ± standard deviation, *p < 0.05, **p < 0.01.
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Induction of ATF3 Expression in HDFs Can
Inhibit Melanoma Cell Growth Both in vitro
and in vivo
The in vivo inhibitory effects of HDFs with high expression of
ATF3 on melanoma formation and growth suggests a potential
new approach for treatment of melanoma in the clinic, namely
inducing tumor stromal cells to increase ATF3 expression.
To test that possibility, we screened several compounds that
were previously reported to induce ATF3 expression and to
play anti-tumor roles, including cyclosporine A (CsA) (23),
cisplatin (38), metformin/phenformin (39), and sulfuretin (40).
We found that two of those compounds, CsA and phenformin,
can significantly induce expression of ATF3 mRNA in HDFs
(Supplementary Figures 4A,C). We chose 1.5mM phenformin
and 10µM CsA as the optimal concentrations for further study
and found that those concentrations induced ATF3 protein
expression within 2 h (Supplementary Figures 4B,D); especially
10µM CsA treatment could result in about 4-fold induction of
ATF3 expression, which is similar to the expression level in ATF3
overexpressing HDF strain 0808 (Figure 2A). To investigate
whether induction of ATF3 expression in HDFs could inhibit
melanoma cell growth, we pretreated HDFs with either CsA or
phenformin, then removed the drugs and continued culturing
the HDFs with complete growth medium. We observed that
ATF3 expression levels in HDFs remained high up to 24 h after
removal of the compounds (Figure 6D) and, importantly, both
compounds suppressed IL-6 and IL-8 mRNA levels for at least
48 h after their withdrawal (Figure 6E), which was confirmed by
ELISA (Figures 6F,G). Then we found that the suppression of IL-
6 expression in HDFs pretreated with either CsA or phenformin
was abolished by deletion of ATF3 (Supplementary Figure 5),
suggesting it depends on the expression of ATF3. Next, to
test whether HDFs pre-treated with CsA or phenformin can
affect melanoma cell growth, we cultured melanoma cells in
CM derived from HDFs that had been treated with either
phenformin or CsA for 24 h followed by continuation of the
HDF culture in the absence of drug for another 48 h before
collection of the CM. We found that CM from HDFs pre-treated
with phenformin or CsA can significantly inhibit the growth
of both Mel-JuSo and UACC62 melanoma cells (Figures 6H,I).
Next, HDFs were pretreated with CsA or DMSO vehicle, mixed
with an equal number of UACC62 melanoma cells and injected
subcutaneously into the back skin of nude/nude mice. Three
weeks after injection, we found that the percentage of mice with
detectable tumors, as well as average tumor sizes weights were
significantly lower in the mice that received HDFs pretreated
with CsA (Figures 6J,K). Taken together, these data suggest
that compounds capable of inducing ATF3 expression in HDFs
could potentially offer a novel treatment strategy for melanoma
in vivo.
DISCUSSION
First described in Paget’s “seed and soil” theory (41), tumor
stromal cells have been well-recognized to play critical roles
in tumor initiation, progression and metastasis (42). Activating
transcription factor 3 (ATF3), a eukaryotic stress response
gene, is a key transcription factor and a member of the
ATF3/cAMP-response element-binding protein family (16, 43).
It has been extensively studied in tumor cells, and the role
of ATF3 in tumor cells has been shown to be cell type-
specific. However, the role of ATF3 in tumor stromal cells
has been little explored so far. Just recently, Kim et al.
investigated ATF3 function in stromal fibroblasts of skin SCC and
found ATF3 deletion in skin fibroblasts were prone to develop
aggressive chemically-induced skin tumors with enhanced CAF
activation (33). Avraham et al. reported that double deletion
of ATF3 and JDP2 in mouse CAFs promoted tumor growth
(17). Our present study revealed that ATF3 expression is low
in stromal cells of clinical melanoma tissues, and human
dermal fibroblasts with overexpression of ATF3 can inhibit
melanoma cell growth and migration both in culture and in
vivo in a mouse model. Our findings further support that
ATF3 in stromal fibroblasts plays a tumor suppressing function
in the skin. It will be interesting to further investigate in
future studies how ATF3 content in stroma cells is involved
in different stages of melanomagenesis and progression. We
also observed strong nuclear staining of ATF3 in melanoma
tumor cells (Figure 1), and we are investigating the role of
intratumoral ATF3 in melanoma growth and progression in a
separate study.
Stromal cells communicate with tumor cells by either direct
cell-cell contact or by soluble factors through paracrine signaling
(44). The soluble factors secreted by stromal cells, including
cytokines and growth factors, play profound roles in tumor
cell growth and migration. Our co-culture and conditioned
medium assays demonstrated that ATF3-overexpressing HDFs
blocked bothMel-JuSo and UACC62melanoma cell proliferation
and migration through a paracrine signaling pathway. It is
well-known that ATF3, a transcriptional repressor, negatively
regulates expression of numerous cytokines in immune cells
(16, 45, 46); also skin dermal fibroblasts with ATF3 deletion
upregulated CAF effector genes including cytokines and
matrix metalloproteases (33). Therefore, we examined these
genes in our system and confirmed that expression of CAF-
related cytokines such as IL-6, IL-8 and COX1/2 were
decreased in ATF3-overexpressing HDFs, and increased in
ATF3-deleted HDFs. Among the genes we investigated, the
negative regulation of IL-6 expression by ATF3 overexpression
in HDFs was the most profound. We found that the addition
of recombinant human IL-6 protein in vitro and in vivo
could reverse the inhibition of melanoma cell growth and
migration by ATF3-overexpressing HDFs. Furthermore, the
JAK/STAT3 pathway, the IL-6 downstream target (47, 48),
was downregulated in ATF3-overexpressing HDFs. IL-6 has
been shown to play a promoting role in the pathogenesis
and development of malignancies in many kinds of tumors,
including melanoma, and was also shown to be highly
expressed by CAFs contacting different tumor types (34, 49–
51). Therefore, we could conclude that the inhibitory effect
of ATF3-overexpressing HDFs on melanoma cell growth and
migration is mainly through the IL-6/STAT3 pathway. However,
we cannot discount that the reductions of other cytokines
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including IL-8, SDF-1 and COX-1/2 in ATF3-overexpressing
HDFs could also contribute to the inhibition of melanoma
growth and migration.
With the recognition of the crucial roles of tumor
microenvironment stromal cells in tumor development,
progression and metastasis, significant efforts have been made in
the last two decades to develop strategies that target the tumor
stroma to improve cancer therapy, however, completely curative
approaches are not currently available (42, 44). Melanoma
has been recognized as an exceptionally aggressive and drug-
resistant skin cancer. Major advances have been made in
therapies for several other cancers, but melanoma remains
difficult to manage. Melanoma cells are often characterized
by an activated extracellular signal–regulated kinase (ERK)
pathway induced by BRAF activating mutations (3, 15). BRAF
inhibitors for treatment of melanoma are effective transiently,
however, most patients develop resistance. Accumulating
evidence suggests that the tumor stroma contributes significantly
to this resistance. Therefore, targeting tumor stroma might be
a potential strategy to prevent BRAF inhibitor resistance (3).
Agents targeting FAP-α, CXCR4/CXCL12, TGF-β, and other
signaling in tumor stroma have been under preclinical study or
clinical trials for various cancers including melanoma (52, 53).
The active mechanisms of these therapeutic approaches are
either through directly inhibiting fibroblast growth or through
targeting signaling pathways involved in stroma-tumor cell
interactions (52, 54). Our study shows not only that artificial
overexpression of ATF3 in normal HDFs suppresses melanoma
cell growth but that, importantly, induced expression of ATF3 in
HDFs by pretreatment with CsA or phenformin, associated with
decreased expression of cytokines, can also inhibit melanoma cell
growth both in vitro and in vivo (Figure 6). Although we cannot
exclude the possibility that other factors induced in HDFs by
pretreatment with CsA or phenformin are involved in inhibiting
tumor cell growth, our results suggest that increased ATF3
expression in HDFs could potentially block tumor cell growth
clinically. Our study provides an opportunity to develop a novel
strategy for melanoma treatment, to specifically induce ATF3
expression in tumor stromal cells, which could be combined with
other conventional and/or innovative treatments to enhance
melanoma therapy in the future.
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